RxDoctor Payments Data

Francis Larosa, MD

Ophthalmology · Richmond, VANPI 1619085214

Payments from drug & device makers

$875in general payments, 2019–2025

Across 26 payments — averaging $33.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$332
  • Alcon$187
  • Rxsight Inc$177
  • AbbVie$97
  • Ocular Therapeutix, Inc.$36
  • Lensar, Inc.$23
  • plus $23 from 2 others

What the payments were for

  • Speaking & faculty fees$20%
  • Food & beverage$872100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$875 in reported general payments places this provider in the 45th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$653,750
Medicare patients
1,499
Services billed
6,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate203$112,591
LumiganBimatoprost186$89,144
RocklatanNetarsudil Mesylat/Latanoprost112$68,569
Brimonidine Tartrate1,066$34,209
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,381$34,148
Alphagan PBrimonidine Tartrate83$30,118
Latanoprost3,034$29,539
CombiganBrimonidine Tartrate/Timolol61$24,607
RestasisCyclosporine29$23,380
Prednisolone Acetate521$20,868
SimbrinzaBrinzolamide/Brimonidine Tart63$19,802
VyzultaLatanoprostene Bunod30$15,953
Travoprost68$14,350
Brinzolamide77$14,041
Dorzolamide Hcl579$11,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan, Restasis$97$167,248359 claims
AlconSimbrinza$187$19,80263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →